.
MergerLinks Header Logo

Announced

Canada Pension Plan Investment Board led a $400m Series C round in insitro.

Financials

Edit Data
Transaction Value£287m
Consideration TypeCash
Capital Owned-
Capital Bid For-
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

United States

Medical Services

drug discovery and development

Domestic

Private Equity

Pending

Minority

Friendly

Acquisition

Venture Capital

Private

Single Bidder

Synopsis

Edit

Canada Pension Plan Investment Board led a $400m Series C round in insitro, a machine learning-driven drug discovery and development company, with participation from Andreessen Horowitz, T. Rowe Price Associates, Casdin Capital, BlackRock, ARCH Venture Partners, Foresite Capital, GV, Third Rock Ventures, Two Sigma Ventures, HOF Capital and Alexandria Venture Investments. Proceeds from the financing will be used to further expand insitro’s platform capabilities and pipeline, providing resources to access enabling datasets, enabling or complementary technologies and platforms, and potential in-licensed assets that have been de-risked by the company’s unique approach to target and patient biomarker discovery.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US